Financially, this project is expected to generate a gross profit margin of approximately 55-60% of the total order value, translating to an estimated profit between Rs 5.5 to Rs 6 crores.

Following a recent share purchase by the promoters, their ownership increased to 2.76 per cent, while public ownership decreased slightly to 97.24 per cent.

From Rs 2.66 per share (52-week low) to today’s intraday high of Rs 5.27 per share, the stock is up by 98.12 per cent.

Delivering a remarkable return of 1,431.10 per cent in just the last three years. The returns in the last year are equally impressive, with an advance of 336.76 per cent.

FII stake increase: Foreign Institutional Investors (FIIs) have increased their stake in Lincoln Pharma from 0.63 per cent in September 2022 to 2.59 per cent in September 2023.

Promoter holding increase: The promoter holding in Lincoln Pharma has also increased from 44.09 per cent in September 2022 to 50.53 per cent in September 2023.

Have you heard about the remarkable journey of a penny sugar stock? In just one year, it skyrocketed from Rs 3.5 to Rs 26, resulting in a jaw-dropping return of 640 per cent. Imagine this: an investment of Rs 1 lakh turned into a staggering Rs 7.42 lakh. What's even more intriguing is the fact that the promoters have increased their stake in the company.